Find Academic Supervisors

Alan SchulmanView profile

Research Professor

• Plant Biology
• Genetics
• Molecular Biology
• +5 more

Alan Schulman is a Research Professor and Research Director at the Institute of Biotechnology within the Faculty of Biological and Environmental Sciences at the University of Helsinki. He serves as a supervisor in three doctoral programs: Integrative Life Science, Sustainable Use of Renewable Natural Resources, and Plant Sciences. His work is centered at the Viikki Plant Science Centre (ViPS), where he leads significant research initiatives in plant genomics and biotechnology. Dr. Schulman earned his Ph.D. in Cell and Developmental Biology from Yale University (1979-1986) and his B.Sc. in Botany from Duke University (1975-1979). He also holds a position as Professor at the Natural Resources Institute Finland, Green Technology Unit VITE, since 2001. His research spans multiple areas of plant science with a focus on plant genomics, crop improvement, and the application of biotechnology in agriculture. Dr. Schulman's work addresses critical challenges in food security, plant disease resistance, and adaptation to climate change. His expertise encompasses plant genetics, molecular biology, and the regulatory aspects of genetically modified organisms. Recent research has particularly emphasized genomic approaches to improve crops like faba bean, barley, oat, and strawberry, with applications in disease resistance, nutritional quality, and environmental adaptation. Dr. Schulman's extensive publication record reflects his leadership in plant genomics and biotechnology. His recent work demonstrates a strong focus on the intersection of genomic technologies, crop improvement, and regulatory science, with particular attention to how new genomic techniques can address agricultural challenges while navigating complex regulatory landscapes. His research bridges fundamental plant science with practical applications for sustainable agriculture. Knight, First Class, Order of the Lion of Finland (2010) Marquis Who's Who in the World (2010) Dr. Schulman actively mentors doctoral students across multiple programs and leads significant research projects funded by the Ministry of Agriculture and Forestry, the Academy of Finland, and other sources. His current projects include Schulman MMM 2022-2026, ViPS: Viikki Plant Science Centre, NaPPI (National Plant Phenotyping Infrastructure), ProFaba (focusing on faba bean breeding), and Papugeno (genomic tools for faba bean improvement). These projects address critical challenges in sustainable protein production, crop resilience, and advanced genomic technologies for plant improvement. As a Principal Investigator in the Viikki Plant Science Centre, Dr. Schulman works within a collaborative research environment that brings together experts across plant sciences. His research group focuses on applying genomic technologies to solve practical problems in crop improvement, with particular expertise in molecular marker development, genome analysis, and the application of new breeding techniques.

• Cardiac Physiology
• Cardiovascular Metabolism
• Heart Failure
• +3 more

Craig Lygate is an Associate Professor of Cardiovascular Physiology at the University of Oxford's Division of Cardiovascular Medicine, leading the 'Cardiac Energetics and Integrative Physiology' research group funded by the British Heart Foundation. His work focuses on understanding cardiac energy metabolism's role in health and disease, particularly exploring therapies for ischaemia and heart failure. He heads the Murine Cardiac Phenotyping Laboratory, using clinical techniques like echocardiography and MRI to assess genetically modified models. Education includes a BSc (Hons), MRes in Biological Sciences (University of Manchester), and a PhD in Cardiovascular Physiology (University of Glasgow). His research combines biochemical assays, cell culture, and collaborative approaches such as genomics and metabolomics, with a current emphasis on the creatine transporter and homoarginine's therapeutic potential. Recent articles highlight advancements in nitric oxide delivery systems for cardiovascular applications and the creatine kinase system's role in cardiac energy provision. Collaborations with Chemistry departments target novel treatments for ischaemia-reperfusion injury. No scientific awards are explicitly listed, but his work has been published in high-impact journals like Circulation and Clinical Science . He advises postgraduate researchers (e.g., Hannah Lake) and oversees grants focused on cardiac energetics. His lab integrates translational research, bridging molecular biology with clinical applications, aiming to translate findings into therapeutic strategies for cardiovascular diseases.

Christopher LeanView profile

Research Fellow

• Philosophy of the Life Sciences
• Bioethics
• Environmental Ethics
• +3 more

Christopher Lean is a Postdoctoral Fellow in the Department of Philosophy at Macquarie University, affiliated with the School of Humanities Ethics and Agency Research Centre and the ARC Centre of Excellence in Synthetic Biology under Prof. Wendy Rogers. His research focuses on the philosophy of life sciences (biology, ecology, medicine) and ethics (bioethics, environment, technology), particularly exploring the role of biotechnology in conservation science and invasive species management. Lean holds a PhD from the Australian National University (2019) in Ecological Kinds and the Units of Conservation. His work bridges philosophy and applied science, addressing ethical dilemmas in biotechnology applications, conservation strategies, and synthetic biology governance. Key research interests include explicit value trade-offs in conservation, the ethics of synthetic biology, and the implications of de-extinction. He has contributed to high-impact journals like Trends in Ecology & Evolution and Cambridge Prisms , focusing on topics such as invasive species ethics, moral hazard in biotechnology, and biodiversity preservation. Lean received the Australian Association of Philosophy Media Prize (2024) and leads the Native Yeast Biobank: A Resource for Synbio Research project (2022–present). His media engagements include expert commentary on The New York Times and ABC's The Philosophers Zone . His academic contributions span interdisciplinary collaborations, emphasizing the intersection of philosophical inquiry and scientific practice in addressing global environmental challenges.

Alex KwanView profile

Associate Professor

• Systems Neuroscience
• Neuroengineering
• Neuropharmacology
• +3 more

Alex Kwan is an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University. Previously, he held positions at Yale School of Medicine and pursued postdoctoral studies as a Croucher Fellow at UC Berkeley. His research integrates systems neuroscience and neuroengineering to study mental health, focusing on drug action in neural circuits, particularly psychedelics like psilocybin and ketamine. He leads the Kwan Lab, which develops optical imaging and behavioral paradigms to visualize neural activity and structure in awake mice. Education: B.A.Sc. in Engineering Physics, Simon Fraser University (2003) Ph.D. in Applied Physics, Cornell University (2009) Research Interests: His work emphasizes understanding how psychiatric drugs modify neural connectivity and function, with applications in preclinical drug development. Key areas include: Psychedelic neurobiology and therapeutic mechanisms Optical imaging of brain-wide neural activity Neural plasticity induced by antidepressants Awards & Grants: One Mind Rising Star Award for Mental Health Research (2022) NIH and Simons Foundation grants Croucher Fellowship (postdoctoral) Lab & Collaborations: The Kwan Lab collaborates with Weill Cornell Medicine and Cornell Neurotech, leveraging interdisciplinary tools like two-photon microscopy and optogenetics. Their long-term goal is to develop safe and effective treatments for depression and anxiety disorders.

Justine Abais-BattadView profile

Assistant Professor

• Hypertension Mechanisms
• Renal Physiology
• Immune-Cardiovascular Interactions
• +3 more

Dr. Justine Abais-Battad is an Assistant Professor in the Department of Physiology at the Medical College of Georgia. She holds a Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University (2014) and a B.S. in Chemistry (2009) from the same institution. Her research focuses on understanding immune mechanisms in hypertension and renal disease, particularly exploring how T cells, dietary factors, and sex differences influence disease progression in animal models like the Dahl salt-sensitive rat. She investigates oxidative stress pathways (NOX2, ROS), gut microbiota interactions, and inflammatory mediators such as CCL2 and TLR4. Key research areas include: Sex-specific hypertension mechanisms Renal damage caused by salt-sensitive conditions Impact of dietary proteins and fibers Role of T cells and immune cells in cardiovascular pathophysiology Her publications from 2022-2024 highlight breakthroughs in: Identifying T cell-derived ROS as key mediators of pregnancy-induced renal damage Demonstrating microbiota's role in sexual dimorphism of hypertension Revealing how corn bedding modifies hypertension phenotypes Awards include the AJP-Renal Early Career Editorial Fellowship (2023) and multiple travel/poster awards from American Heart Association and APS conferences. She serves on NIH review panels and AHA committees, contributing to policy and grant evaluation. Teaching responsibilities include BIOM 8030 Experimental Therapeutics.

Narasimman GurusamyView profile

Assistant Professor

• Epigenetics
• Cardiac diseases
• non-coding RNA
• +3 more

Dr. Narasimman Gurusamy is an Assistant Professor at the Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, specializing in Pharmaceutical Sciences. He holds a Ph.D. in Pharmaceutical Sciences from Niigata University of Pharmacy and Applied Life Sciences (Japan) and completed postdoctoral training at UConn Health Center, Harvard Medical School, and University of Tennessee Health Science Center. Education: M.Pharm (Tamil Nadu Dr. MGR Medical University, India), Ph.D. (Niigata University, Japan) Research Focus: Epigenetic mechanisms in cardiac diseases, non-coding RNA regulation, exosome therapy, stem cell biology, and gene-environment interactions His work explores how long non-coding RNAs and epigenetic modifiers influence cardiac repair, particularly through induced mesenchymal stem cells and their exosomal signaling . Current projects investigate dietary and environmental impacts on epigenetic changes in the heart. Recent publications highlight advancements in RNA-based therapies and metabolic interventions for cardioprotection. Scientific Awards: American Heart Association Career Development Award, Young Research Scientist Award, Travel Awards Dr. Gurusamy serves as Grant Reviewer for the American Heart Association, Associate Editor for Frontiers in Cardiovascular Medicine , and Vice-Chair for the Communication Committee of the Society for South Asian Heart Research (SAHR). His lab employs in-vitro, in-vivo, and clinical trial approaches, utilizing PCR, ELISA, flow cytometry, and genomic repository analyses.

• Metabolic Disease
• Epigenetics
• Cardiovascular Disease
• +3 more

Brad Ferguson is an Associate Professor in the Department of Environmental Sciences & Health at the University of Nevada, Reno. His research investigates the epigenetic mechanisms linking metabolic diseases like obesity and diabetes to cardiac remodeling, with a focus on histone deacetylases (HDACs), acetyltransferases (HATs), and dietary bioactives. Key techniques: bioinformatics, cell culture, animal models. Primary research themes: chromatin regulation, metabolic-cardiovascular crosstalk, microbiome-epigenome interactions. The lab emphasizes dietary epigenetic modifiers and translational approaches to develop therapies for cardio-metabolic disorders. Recent publications highlight intersections between: Epigenetic aging and caloric restriction HDAC inhibition in cardiac/hypertension models Muscle physiology and post-translational modifications Nutritional programming in livestock and human systems No scientific awards were explicitly documented in the provided materials.

• Cardiac Metabolism
• Diabetic Cardiomyopathy
• Mitochondrial Metabolism
• +3 more

Lisa Heather is an Associate Professor and British Heart Foundation (BHF) Intermediate Fellow at the University of Oxford's Department of Physiology, Anatomy, and Genetics (DPAG) within the Medical Sciences Division. Her research focuses on cardiac metabolism in health and disease, particularly in diabetes and heart failure. She holds dual expertise in molecular mechanisms of metabolic dysfunction and translational cardiovascular research. Dr. Heather earned a Bachelor's degree in Medical Biochemistry from the University of Surrey and conducted doctoral research on cardiac hypertrophy's metabolic origins. Her postdoctoral work explored mitochondrial dysfunction in diabetic cardiomyopathy. Key career milestones include a Diabetes UK RD Lawrence Fellowship (2011) and a BHF Intermediate Fellowship (2018), supporting her investigations into lipid metabolism and hypoxia signaling in diabetic hearts. Her research interests span mitochondrial bioenergetics, fatty acid trafficking, hypoxia responses, and metabolic reprogramming in disease. She employs advanced techniques like hyperpolarized MRI and metabolomics to study real-time metabolic changes, with recent breakthroughs identifying novel roles for fatty acids in disrupting hypoxia signaling and cardiomyocyte function. Her publications (e.g., Diabetes , Physiological Reviews , JCI Insight ) highlight interdisciplinary approaches to metabolic disease. She leads the Heather Group, advancing therapies targeting metabolic pathways in heart failure and diabetes. Her work bridges basic science and clinical applications, emphasizing metabolic interventions for cardiovascular health.

David R. DeyleView profile

Associate Professor

• Gene Therapy
• Cell Therapy
• Genomic Editing
• +12 more

David R. Deyle, M.D., is an Associate Professor of Medical Genetics at Mayo Clinic in Rochester, Minnesota. He holds primary and joint appointments as a Consultant in the Department of Medical Genetics, Department of Molecular Medicine, Department of Cardiovascular Medicine, Department of Orthopedic Surgery, and Department of Pediatric and Adolescent Medicine. His multidisciplinary role reflects his integrative research in gene and cell therapy for genetic disorders. Dr. Deyle earned his M.D. from the University of Minnesota Medical School, completed residency in Internal Medicine and Pediatrics at the University of Minnesota, and underwent fellowship training in Medical Genetics at the University of Washington, Seattle. He is board-certified in Clinical Genetics and Genomics by the American Board of Medical Genetics and Genomics. His research focuses on developing gene and cell therapies through genomic editing in human stem cells. Key areas include treating osteogenesis imperfecta using iPSCs and AAV vectors, in vivo modeling of skeletal diseases, and oncolytic measles virus (MV-NIS) therapy for neurofibromatosis 1 (NF1) tumors. His work leverages CRISPR, TALENs, and adeno-associated virus (AAV) technologies to precisely modify the genome in mesenchymal and induced pluripotent stem cells for regenerative medicine applications. Analysis of his recent publications reveals a strong trend in clinical genomics, stem cell engineering, and translational gene therapy. His work spans rare genetic disorders such as Ehlers-Danlos syndrome, achondroplasia, and mucopolysaccharidosis, with a consistent emphasis on improving diagnostic and therapeutic pipelines through genomic innovation. Discovery Science Award, Regenerative Medicine Minnesota (2020–2022) Gene Therapy of Arthritis and Related Disorders Young Investigator Award (2008) NIH Loan Repayment Program Grant (2006) Summa Cum Laude, University of Minnesota (1993) Dr. Deyle has served as Principal Investigator on multiple NIH-funded grants, including projects on in vivo gene targeting for inherited bone disease and engineering pluripotent stem cells for osteogenesis imperfecta. He has also been a mentor and committee member in the American Society of Gene & Cell Therapy and has reviewed grants for NIH study sections (NIAMS, NINDS, NCMRR). His laboratory is part of the Center for Individualized Medicine and the Center for Regenerative Biotherapeutics at Mayo Clinic, where his team develops preclinical models and novel viral vector systems for genetic correction.

Judith StorchView profile

Professor

• Lipid Metabolism
• Molecular Nutrition
• Metabolic Diseases
• +4 more

Judith Storch is a Distinguished Professor of Nutritional Sciences at Rutgers University, leading groundbreaking research on intracellular lipid trafficking with direct implications for metabolic diseases including obesity, cardiovascular disorders, and lipid-storage pathologies. Her work focuses on molecular mechanisms of fatty acid-binding proteins (FABP) and Niemann-Pick type C2 protein (NPC2) in cellular lipid transport. Education: Ph.D. in Biochemistry, Columbia University, 1983 Dr. Storch's research program investigates how lipids such as fatty acids and cholesterol are transported within cells, employing transgenic mouse models, patient-derived cells, and advanced biophysical techniques. Her laboratory examines why different cell types express distinct FABP isoforms, how intestinal FABP regulates whole-body energy homeostasis, and NPC2's critical role in cholesterol egress from lysosomes. Current work explores phospholipid-based therapies for Niemann-Pick disease using LBPA enrichment to restore cellular homeostasis. Analysis of her 2018-2021 publications reveals consistent focus on lipid-storage diseases with emphasis on NPC pathology and FABP functions. Key breakthroughs include demonstrating LBPA's therapeutic potential for NPC1 deficiency, establishing RBP2's role in gut signaling and weight regulation, and uncovering metabolic adaptations in FABP-knockout models that confer protection against diet-induced metabolic dysfunction. Scientific Awards: No specific awards documented in source material Dr. Storch directs a multidisciplinary research team utilizing biochemical, biophysical, and molecular approaches to address fundamental questions in lipid metabolism. Her laboratory maintains active collaborations with clinical researchers studying Niemann-Pick disease and develops translational strategies targeting lipid trafficking defects. Current NIH-funded projects investigate phospholipid therapeutics for lysosomal storage disorders and mechanisms linking fatty acid transport to metabolic disease pathogenesis. Her laboratory integrates site-directed mutagenesis, fluorescence spectroscopy, confocal microscopy of Caco-2 intestinal cells, and whole-animal physiology to dissect lipid transport pathways. Ongoing work examines how specific phospholipids modulate NPC protein function and explores FABP isoforms as metabolic regulators in obesity-related pathologies, with therapeutic applications for cardiovascular disease and rare lipid-storage disorders.

• Nephrology
• Renal Physiology
• Membrane Transport
• +7 more

Peter S. Aronson is the C. N. H. Long Professor of Medicine (Nephrology) and Professor of Cellular and Molecular Physiology at Yale School of Medicine. He holds primary appointments in the Department of Internal Medicine and secondary appointments in Cellular & Molecular Physiology and the MD-PhD Program. He has been a faculty member at Yale since 1977 and served as Chief of the Section of Nephrology from 1987 to 2002. Department: Internal Medicine (Nephrology) School: Yale School of Medicine University: Yale University Academic Rank: Professor Email: peter.aronson@yale.edu Dr. Aronson's research focuses on the molecular and physiological mechanisms regulating renal electrolyte transport, particularly sodium, acid-base, and oxalate excretion. His work centers on membrane transporters such as NHE isoforms (Na + -H + exchangers) and SLC26 anion exchangers. He employs approaches including isoform-specific antibody development and genetically modified mouse models to study transporter function in vivo. His investigations into SLC26A6 have elucidated its critical role in oxalate homeostasis and calcium oxalate kidney stone formation. His recent publications (2021–2024) emphasize oxalate metabolism, its systemic effects in dialysis patients, and genetic determinants of transporter function. Themes include the link between elevated oxalate and sudden cardiac death, the role of macrophages in oxalate release, and the physiological modeling of intestinal oxalate transport. These studies span molecular physiology, clinical nephrology, and translational research, reflecting a cohesive trajectory in understanding electrolyte and anion handling in health and disease. Dr. Aronson has received numerous scientific honors, including: Homer W. Smith Award, American Society of Nephrology (1994) Robert W. Berliner Award, American Physiological Society (2016) Walter B. Cannon Award, American Physiological Society (2019) Fellow, American Academy of Arts and Sciences (2009) Fellow, American Association for the Advancement of Science (1996) Young Investigator Award, ASN and AHA (1985) Charles W. Bohmfalk Teaching Prize (2005) Fund for Physician-Scientist Mentorship Award (2023) Dr. Aronson is deeply involved in academic leadership and education. He served as President of the American Society of Nephrology in 2008 and is currently an Associate Director of the Yale M.D.-Ph.D. Program. He has been recognized for excellence in teaching and mentorship, advising numerous students and trainees. His research is conducted in collaboration with a strong network of co-investigators, including Felix Knauf, Tong Wang, and Robert Thomson, and is supported by sustained funding in the field of renal physiology. His laboratory investigates ion transport mechanisms using molecular, cellular, and whole-animal models, with a particular focus on the kidney’s role in systemic electrolyte and acid-base balance. The team combines biochemical, immunological, and genetic techniques to dissect transporter function and regulation.

• Computational Biology
• Bioinformatics
• Gene Regulation
• +4 more

Lihua Julie Zhu is a Professor and the head of Bioinformatics Core in the Department of Molecular, Cell and Cancer Biology at UMass Chan Medical School (UMMS). She also holds positions in the T.H. Chan School of Medicine, Program in Molecular Medicine, Interdisciplinary Graduate Program, and Bioinformatics and Integrative Biology program. With an interdisciplinary background spanning nutritional sciences and computer science, Dr. Zhu leads a research program focused on computational biology and bioinformatics methodologies for genomic data analysis. Dr. Zhu's educational background includes: BS in Animal Nutrition from China Agricultural University, Beijing MS in Animal Nutrition from China Agricultural University, Beijing MS in Computer Science from DePaul University, Chicago PhD in Nutritional Sciences from University of Wisconsin-Madison Dr. Zhu's research focuses on understanding gene regulation and cancer etiology through the development and application of computational tools for analyzing high-throughput genomic datasets. Her lab specializes in mining and integrating various genomic technologies including WGS, ChIP-seq, bulk and single cell RNA-seq, and ATAC-seq. A key strength of her research program is algorithm development, with her team having created over 20 computational tools, including numerous Bioconductor packages that serve the broader research community. Analysis of Dr. Zhu's recent publications (2024-2025) reveals a strong emphasis on both methodological innovation and biological discovery. Her work spans cancer biology, genome editing technologies, and computational tool development across multiple biological systems. A significant portion of her recent publications involve the creation of specialized bioinformatics tools for analyzing complex genomic datasets, demonstrating her dual commitment to advancing computational methodology while making biological discoveries. Dr. Zhu leads the Bioinformatics Core facility at UMass Chan Medical School, providing essential computational expertise and support to researchers across the institution. The core facility plays a critical role in enabling sophisticated genomic analyses for numerous research projects requiring advanced computational approaches to analyze complex biological data.

• Gene Therapy
• Fetal Medicine
• Medical Biotechnology
• +5 more

Simon Waddington is a Professor of Gene Therapy at the University College London (UCL) within the Ega Institute for Women's Health and Faculty of Population Health Sciences . His work bridges gene therapy , maternal-fetal medicine , and genetic disorder research . Research interests focus on translational gene therapy for childhood inherited diseases , particularly neurodegenerative disorders , metabolic conditions , and lysosomal storage diseases . Key areas include viral vector engineering (AAV, lentivirus), placental-targeted therapies , and mitochondrial dysfunction interventions. His 150+ peer-reviewed publications grants exceeding £20M patent filings (x8) highlight achievements in journals like Nature , Science Translational Medicine , and Blood . Articles reveal trends in AAV-mediated gene delivery , preterm birth models , and multi-organ disease targeting . Collaborations span European Research Council , Medical Research Council , LifeArc , and institutions in Singapore, South Africa, and across Europe. He chairs UCL's Cell and Gene Therapy Therapeutic Innovation Network and co-founded Bloomsbury Genetic Therapies .

Mary Lauren BentonView profile

Assistant Professor

• Computational Biology
• Gene Regulation
• Biomedical Informatics
• +3 more

Dr. Mary Lauren Benton is an Assistant Professor in the Department of Computer Science at Baylor University's College of Engineering and Computer Science. She holds a Ph.D. and M.S. in Biomedical Informatics from Vanderbilt University (2020, 2018) and a B.S.I. in Bioinformatics from Baylor University (2015). Education: Ph.D. (Vanderbilt, 2020), M.S. (Vanderbilt, 2018), B.S.I. (Baylor, 2015) Her research focuses on computational biology and gene regulation, particularly how DNA sequences influence genome function and human disease risk through integrated datasets. Recent work explores enhancer-gene interactions, epigenetic mechanisms, and the application of graph neural networks to genomic problems. Selected publications highlight interdisciplinary trends across genomics (e.g., Cis-regulatory landscapes , CTCF motif accessibility ) and computer science (e.g., Dynamic graph attention , Node classification ).

Krystyna GieniecView profile

Research Fellow

• Breast Cancer Biology
• Calcium Signaling
• Mammary Gland Development
• +3 more

Dr. Krystyna Gieniec is an NHMRC Emerging Leadership Level 1 Fellow at the University of New South Wales, Faculty of Medicine and Health. She conducts her research in the EMBL-Australia Calcium Signalling Laboratory under the mentorship of Dr. Felicity Davis. Her work focuses on mammary gland development and breast cancer biology, with particular emphasis on calcium signaling mechanisms and stromal-epithelial interactions. Dr. Gieniec's research interests center on understanding how epithelium and adjacent stroma interact via calcium-induced signals to promote mammary development at both embryonic and cancerous stages. Her laboratory employs genetically modified animal models and complex 3D cell systems coupled with advanced 3D volumetric microscopy imaging to investigate these processes. Her work bridges developmental biology and cancer research, with implications for understanding tumor microenvironment dynamics and potential therapeutic interventions. Dr. Gieniec has received numerous prestigious awards recognizing her research excellence, including the Nikon Award for best oral presentation, UNSW SBMS Young Researcher of the Year Award, and multiple imaging competition awards for her microscopy work. Her research has been recognized through various scholarship programs throughout her career. Nikon Award for best 10-minute oral presentation (SBMS Research Symposium, 2023) UNSW Faculty of Medicine and Health Values in Action - Diversity Award (team, 2023) UNSW SBMS Young Researcher of the Year Award (2022) Cover image for BBA Molecular Cell Research (2022) Multiple microscopy imaging competition awards (2021-2022) Research Training Program Stipend (2017-2020) Dr. Gieniec has secured significant research funding including the NHMRC Emerging Leadership Level 1 Investigator Grant (2023-2028) as Chief Investigator A. She has also been involved in the 'The Illuminators' virtual microscopy exhibition for UNSW Diversity Fest in both 2021 and 2023, demonstrating her commitment to science communication and diversity in STEM. Her research program combines advanced imaging techniques with developmental biology approaches to unravel complex signaling mechanisms in mammary gland development and breast cancer.